RJA
AVDL

Raymond James & Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Raymond James & Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,141
Closed -$83K – 3953
2022
Q2 		$83K Buy
+34,141
New +$140K ﹤0.01% 3714

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Raymond James & Associates's AVDL Position: Q3 2022 in Review

Raymond James & Associates sold out of Avadel Pharmaceuticals (AVDL) in Q3 2022, closing a stake of 34,141 shares — an estimated $83K sold.

Raymond James & Associates first reported a position in AVDL in Q2 2022 and held it in 1 quarter. The position peaked at $83K in Q2 2022. 76 funds tracked by Wall St. Rank hold AVDL as of Q3 2022.

  • Raymond James & Associates reported no remaining Avadel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 34,141 Avadel Pharmaceuticals shares in Q3 2022, an estimated $83K.
  • Raymond James & Associates first reported a position in Avadel Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Raymond James & Associates's Avadel Pharmaceuticals position peaked at $83K in Q2 2022.
  • 76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.